Alfuzosin

Also known as: Alfuzosin hydrochloride

Active ingredient description

Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Alfuzosin
G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA01

Medicines

Alfuzosin is the active ingredient of these drugs:

Drug
Countries

Poland

Poland

Cyprus Hong Kong

Poland

Poland

Poland

Spain

United Kingdom

Poland

Italy

United Kingdom

Hong Kong Tunisia

Italy

Italy

Singapore

Spain

France

Tunisia

Germany United States

United Kingdom

Hong Kong

Tunisia

Ireland

Australia Austria Brazil Canada Cyprus

United Kingdom

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

90347YTW5F - ALFUZOSIN

CAS registry number

81403-68-1 - Alfuzosine hydrochloride

81403-80-7 - alfuzosin

SNOMED-CT

395954002 - Alfuzosin (substance)